Firas Koura, MD
Pulmonary Disease · Georgetown, KYNPI 1790888683
Payments from drug & device makers
Across 867 payments — averaging $488.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$173K
- AstraZeneca$131K
- Grifols USA, LLC$76K
- Shire North American Group Inc$16K
- Boehringer Ingelheim$10K
- Sunovion Pharmaceuticals Inc.$8K
- plus $9K from 30 others
What the payments were for
- Consulting fees$17,8125%
- Speaking & faculty fees$295,43584%
- Travel & lodging$20,9076%
- Food & beverage$15,7184%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 238 | $172,729 |
| AstraZeneca | 231 | $131,060 |
| Grifols USA, LLC | 161 | $76,188 |
| Shire North American Group Inc | 27 | $16,141 |
| Boehringer Ingelheim | 48 | $10,245 |
| Sunovion Pharmaceuticals Inc. | 37 | $7,570 |
| Sanofi | 18 | $2,019 |
| Merck | 2 | $1,246 |
| Grifols Shared Services North America, Inc. | 5 | $1,048 |
| Fisher & Paykel Healthcare Limited | 1 | $700 |
| ZOLL Medical Corporation | 2 | $650 |
| BD | 1 | $533 |
| Mylan Specialty L.p. | 24 | $520 |
| Amgen | 13 | $398 |
| Vertex | 1 | $325 |
| Baxter Healthcare | 1 | $300 |
| Regeneron Healthcare Solutions, Inc. | 7 | $281 |
| Insmed, Inc. | 4 | $176 |
| Silk Road Medical, Inc. | 1 | $167 |
| Genentech USA, Inc. | 7 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Pulmonx Corporation | 4 | $97 |
| Inogen, Inc. | 3 | $87 |
| CSL Behring | 3 | $78 |
| Pfizer | 3 | $60 |
| AbbVie(2 entities) | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Mallinckrodt Enterprises LLC | 3 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Philips North America LLC | 2 | $29 |
| Werfen USA LLC | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$119,350
- Prolastin-C Liquid$64,372
- BREZTRI$55,703
- GLASSIA$15,767
- ANORO$15,732
- Prolastin-C$10,545
- LONHALA MAGNAIR$6,971
- FASENRA$6,896
- DUPIXENT$1,665
- FISHER & PAYKEL HEALTHCARE$700
- TEZSPIRE$365
- IPS - Liquid Premix$300
- ENROUTE Transcarotid Neuroprotection System$167
- ENHANCE Transcarotid Peripheral Access Kit$167
- ENROUTE .014 Guidewire$167
- ENROUTE Transcarotid Stent$167
- AIRSUPRA$116
- ANORO ELLIPTA$112
How this compares
$423,245 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $185,594 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $45,762 |
| XembifyImmune Globulin,gamma(Igg)klhw | 12 | $42,762 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $34,556 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $30,553 |
| XolairOmalizumab | 12 | $24,929 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $21,874 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,658 |
| Pirfenidone | 12 | $8,041 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $4,584 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,055 |
| Roflumilast | 57 | $2,474 |
| Ventolin HfaAlbuterol Sulfate | 19 | $2,284 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $172,729 | $245,080340 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $10,245 | $54,42177 claims |
| Grifols USA, LLCXembify | $76,188 | $42,76212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $131,060 | $37,22259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Georgetown
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.